cancer, clinical trials

A government investigation concludes that Anil Potti faked data on multiple grants and papers.

The National Cancer Institute is launching a Phase 2 trial matching patients with specific mutations to drugs tailored to those genetic changes.

Phase 3 data from a clinical trial show a positive response to a melanoma treatment based on a modified herpesvirus.

The largest and longest study of long-term, regular aspirin use finds that the drug may lead to a modestly reduced risk for some types of gastrointestinal cancers.

Even when a clinical trial fails, some patients improve. What can researchers learn from these exceptional responders?

Scientist to Watch Yvonne Saenger explains recent advances in using biomarkers to identify cancer patients who might benefit most from immunotherapy.

A panel of oncologists discusses cases of exceptional responders, or cancer patients whose tumors disappear after a brief period of chemotherapy.

Preemptive detection and intervention will be key to easing the growing burden of cancer, particularly in developing countries.

IBM’s cognitive computer will be individualizing trial plans for cancer patients at the Mayo Clinic.

Considering “targeted therapeutics” in the face of intra-patient heterogeneity. 

At AACR, scientists discuss the growing interest in nanotechnology and how it can be used to study, diagnose, and treat cancer.

Investigational drug that inhibits proteins involved with epigenetic regulation shows activity against certain blood cancers in an early-stage clinical trial.

Antibody barcoding allows scientists and clinicians to analyze protein expression in small amounts of cancer tissue.

Immunotherapies, such as the re-engineered T cells that last year saved a 7-year-old girl’s life, continue to show promise as cancer treatments.

A blood test for the protein CA-125, coupled with a vaginal ultrasound, can help detect the difficult-to-spot cancer.

Advances in genomics and cancer biology will alter the design of human cancer studies.

A decade into the age of genomics, science is generating a flood of data that will help in the quest to eradicate the disease.

Renowned cancer researcher Lewis Cantley is leaving Harvard to lead a new cancer center at Weill Cornell Medical College and NewYork-Presbyterian Hospital.

A former manager at Genentech claims the company bypassed ethical and clinical guidelines in order to rush a promising drug through clinical trials.

A trial comparing the effectiveness of robotic surgery and radiation for the treatment of throat cancer has begun in Canada.